Back to search

Ireland· IE-PA-PA1760/001/002

Dacarbazine Lipomed 500 mg powder for solution for infusion

A dacarbazine product containing dacarbazine, registered in Ireland by Lipomed GmbH. The same ATC class is registered in 15 of our 19 countries.

ATC L01AX04

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedDacarbazine Lipomed 500 mg powder for…ATCL01AX04REGISTER NO.IE-PA-PA1760/001/002PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Dacarbazine is registered in 15 of 19 countries.

Countries holding a registration under ATC L01AX04 (dacarbazine), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 8 of them publish a price we can compare per daily dose

Dacarbazine · ATC L01AX04

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of dacarbazine costs, country by country.

Normalised to the WHO defined daily dose (43.3 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Dacarbazine · price per daily dose (43.3 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$5.12
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

HPRA (Ireland)
Active substance
Dacarbazine
Manufacturer
Lipomed GmbH
Country
Ireland (IE)
ATC code
L01AX04
ATC class
Dacarbazine
Defined daily dose
43.3 mg, P
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    PA1760/001/002

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

237 interactions on record for dacarbazine.

Graded by severity as the source publishes them — 35 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Dacarbazine · interactions on record

237 records

  • 35 severe
  • 114 moderate
  • 14 minor
  • 74 info

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • Nalidixic acidJ01MB02severe
  • CladribineL01BB04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Dacarbazine in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dacarbazine products

Authorised across Europe · EMA

The same active substance is authorised in 19 EEA countries. Names it is sold under:

  • Austria · Dacarbazin Lipomed, Dacarbazine Medac
  • Belgium · Dacarbazine, Dacarbazine Medac
  • Cyprus · Dacarbazine Lipomed
  • Czechia · Dacarbazine Medac
  • Germany · Dacarbazin Lipomed, Detimedac
  • Denmark · Dacarbazine Lipomed, Dacarbazine Medac
  • Spain · Dacarbazina Accord, Dacarbazina Medac
  • Finland · Dacarbazine Lipomed, Dacarbazine Medac
  • France · Dacarbazine Accord, Dacarbazine Lipomed
  • United Kingdom (Northern Ireland) · Dacarbazine Medac
  • Hungary · Dacarbazine Accord, Dacarbazine Lipomed
  • Italy · Dacarbazina Lipomed, Dacarbazina Medac
  • Netherlands · Dacarbazine Medac
  • Norway · Dacarbazine Lipomed
  • Poland · Detimedac
  • Portugal · Dacarbazina Medac
  • Romania · Dacarbazina Lipomed
  • Sweden · Dacarbazine Medac
  • Slovakia · Dakarbazín Medac

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/463c5da7-b9a2-4f60-b0d0-a14c2564d236
GET /v1/drugs/463c5da7-b9a2-4f60-b0d0-a14c2564d236?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Powder for solution for infusion",
  "routes": [
    "Intravenous use"
  ],
  "source": "hpra",
  "atc_all": [
    "L01AX",
    "L01AX04"
  ],
  "strength": null,
  "pa_number": "PA1760/001/002",
  "substances": [
    "Dacarbazine"
  ],
  "legal_basis": "Generic application (Article 10(1) of Directive No 2001/83/EC)",
  "market_info": "Marketed",
  "authorised_at": "18/08/2017",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about dacarbazine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.